Actively Recruiting
Randomized Controlled Study to Evaluate LXE408 for Chronic Chagas Disease Without Severe Organ Dysfunction Comparing Safety and Efficacy to Benznidazole and Placebo
Led by Novartis Pharmaceuticals · Updated on 2026-10-15
130
Participants Needed
22
Research Sites
182 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the drug LXE408 in people with chronic Chagas disease who do not have severe organ dysfunction. This phase 2, randomized, participant- and investigator-blinded study compares LXE408 to placebo and the standard treatment benznidazole. The goal is to assess the drugs ability to clear or reduce parasites in the blood, as well as its safety, tolerability, pharmacokinetics, and pharmacodynamics. Participants are assigned to one of four groups LXE408 for 28 days, LXE408 for 14 days followed by placebo for 14 days, placebo for 28 days, or benznidazole for 60 days. The study involves oral administration of these treatments in a parallel group design. The treatment period is followed by monitoring to evaluate the effects and parasite clearance over time. During the study, participants undergo PCR testing at months 2, 4, 6, and 12 to check for sustained parasitological clearance. Other assessments include monitoring adverse events, blood drug levels at various days during treatment, and serology tests at months 6 and 12. The study also tracks participant health for up to 48 months to observe long-term outcomes and safety. Total participation may last several years including treatment and follow-up.
CONDITIONS
Brief Title
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here